Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis

Hui, Fuhai; Zhang, Yingshi; Ren, Tianshu; Li, Xiang; Zhao, Ming

doi:10.1007/s00228-018-2593-3

Cited by 36 publications

(32 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the same daily dose of metformin as used in the present study administered to prediabetic patients effectively reduced plasma glucose levels and improved insulin sensitivity without inducing serious adverse effects in our previous study 45,47 . What is more, 3 g metformin daily for 6 months was found to be not only safe but also the most effective option for reducing body weight and improving glucose homeostasis in overweight and obese subjects without diabetes 48 . Taking into account that high‐dose metformin treatment is frequently prescribed to patients with type 2 diabetes, 31 it seems that the beneficial effect of the combination therapy may be observed in diabetic subjects and we intend to verify this question in our future studies.…”

Section: Discussionsupporting

confidence: 52%

The impact of combination therapy with metformin and exogenous vitamin D on hypothalamic‐pituitary‐thyroid axis activity in women with autoimmune thyroiditis and high‐normal thyrotropin levels

Krysiak

Kowalcze

2020

J Clin Pharm Ther

View full text Add to dashboard Cite

What is known and objective Metformin was found to decrease thyrotropin levels in subjects with non‐autoimmune but not with autoimmune hypothyroidism. Vitamin D reduced thyroid autoimmunity without affecting thyrotropin and thyroid hormone levels. The aim of the current study was to investigate whether exogenous vitamin D modulates the impact of metformin on hypothalamic‐pituitary‐thyroid axis activity in young women with autoimmune thyroiditis. Methods This case‐control study included 32 prediabetic women with Hashimoto's thyroiditis, high‐normal thyrotropin levels (2.5‐4.5 mIU/L) and vitamin D insufficiency. Based on patient preference, these individuals received either metformin (3 g daily) plus vitamin D (4000 IU daily) (n = 17) or were treated with only metformin (3 g daily) (n = 15). Plasma levels of glucose, serum levels of insulin, thyrotropin, total and free thyroid hormones and 25‐hydroxyvitamin D, as well as serum titres of thyroid antibodies, were assessed at baseline and 6 months later. Results and discussion Thirty‐one women completed the study. At baseline, there were no differences between the treatment groups. In both study arms, metformin reduced plasma glucose levels and improved insulin sensitivity but this effect was stronger in subjects receiving vitamin D. Only metformin administered with vitamin D decreased thyrotropin levels, increased 25‐hydroxyvitamin D levels and reduced thyroid antibody titres. The impact on thyrotropin and antibody titres correlated with the increase in 25‐hydroxyvitamin D levels and with the improvement in insulin sensitivity. What is new and conclusion This study has shown for the first time that exogenous vitamin D potentiates the impact of metformin on thyrotropin levels in women with autoimmune thyroiditis.

show abstract

Section: Discussionsupporting

confidence: 52%

The impact of combination therapy with metformin and exogenous vitamin D on hypothalamic‐pituitary‐thyroid axis activity in women with autoimmune thyroiditis and high‐normal thyrotropin levels

Krysiak

Kowalcze

2020

J Clin Pharm Ther

View full text Add to dashboard Cite

show abstract

“…In line with these results, metformin-induced weight loss in obese rats (21) and mice (22) and, decreased body mass in chickens (23). Moreover, a growing body of evidence demonstrates that metformin induces a modest weight loss in human beings (24)(25)(26). In this regard, the current study confirms the anorectic effect of mazindol and metformin individually in the sweetened milk intake test in rats.…”

Section: Anorectic Effects Of Mazindol and Metformin Alonesupporting

confidence: 86%

Efficacy and safety of the metformin-mazindol anorectic combination in rat

et al. 2020

View full text Add to dashboard Cite

The current study investigates the anorectic interaction and safety of the mazindol-metformin combination in rats. Isobologram and interaction index were used to determine anorectic interaction between mazindol and metformin in the sweetened milk model. The safety profile of the mazindol-metformin combination was determined by measuring anxiety, blood pressure, hematic biometry and blood chemistry. An acute dose of mazindol and metformin administered per os, individually or as a mixture, has reduced the milk consumption in rats in a dose-dependent manner. Theoretical effective dose 40 (ED40t) did not differ from the experimental effective dose 40 (ED40e) obtained with the mazindol-metformin mixture in the anorexia experiments, by Student′s t-test. In addition, the interaction index confirmed the additive anorectic effect between both drugs. A single oral dose of ED40e mazindol-metformin mixture induced anxiolysis in the elevated plus-maze test. Moreover, oral administration of mazindol-metformin combination for 3 months significantly decreased glycemia, but not blood pressure nor other parameters of hematic biometry and blood chemistry. Results suggest that mazindol-metformin combination exerts an additive anorectic effect, as well as anxiolytic and hypoglycemic properties. Mazindol-metformin combination might be useful in obese patients with anxiety disorders or diabetes risk factors.

show abstract

“…Third, metformin can the inflammatory response [ 82 ]. Additionally, metformin reduces the risk of adverse outcomes in COVID-19 patients by reducing BMI and body weight [ 83 ].…”

Section: Discussionmentioning

confidence: 99%

Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis

2021

View full text Add to dashboard Cite

Background The coronavirus disease 2019 (COVID-19) pandemic has led to global research to predict those who are at greatest risk of developing severe disease and mortality. The aim of this meta-analysis was to determine the associations between obesity and the severity of and mortality due to COVID-19. Methods We searched the PubMed, EMBASE, Cochrane Library and Web of Science databases for studies evaluating the associations of obesity with COVID-19. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using random- or fixed-effects models. Meta-regression analyses were conducted to estimate regression coefficients. Results Forty-six studies involving 625,153 patients were included. Compared with nonobese patients, obese patients had a significantly increased risk of infection. (OR 2.73, 95% CI 1.53–4.87; I2 = 96.8%), hospitalization (OR 1.72, 95% CI 1.55–1.92; I2 = 47.4%), clinically severe disease (OR 3.81, 95% CI 1.97–7.35; I2 = 57.4%), mechanical ventilation (OR 1.66, 95% CI 1.42–1.94; I2 = 41.3%), intensive care unit (ICU) admission (OR 2.25, 95% CI 1.55–3.27; I2 = 71.5%), and mortality (OR 1.61, 95% CI 1.29–2.01; I2 = 83.1%). Conclusion Patients with obesity may have a greater risk of infection, hospitalization, clinically severe disease, mechanical ventilation, ICU admission, and mortality due to COVID-19. Therefore, it is important to increase awareness of these associations with obesity in COVID-19 patients.

show abstract

Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis

Cited by 36 publications

References 82 publications

The impact of combination therapy with metformin and exogenous vitamin D on hypothalamic‐pituitary‐thyroid axis activity in women with autoimmune thyroiditis and high‐normal thyrotropin levels

The impact of combination therapy with metformin and exogenous vitamin D on hypothalamic‐pituitary‐thyroid axis activity in women with autoimmune thyroiditis and high‐normal thyrotropin levels

Efficacy and safety of the metformin-mazindol anorectic combination in rat

Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis

Contact Info

Product

Resources

About